Inhibition of rat prostate carcinogenesis by a 5α-reductase inhibitor, FK143

Journal of the National Cancer Institute

Volumn 89, Issue 11, 1997, Pages 803-807

  Homma, Yukio ^a,c   Kaneko, Masashi ^a   Kondo, Yasushi ^a   Kawabe, Kazuki ^a   Kakizoe, Tadao ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [3 [BIS(4 ISOBUTYLPHENYL)METHYLAMINO]BENZOYL] 1H INDOL 1 YL]BUTYRIC ACID; STEROID 5ALPHA REDUCTASE INHIBITOR;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CONTROLLED STUDY; HORMONAL CARCINOGENESIS; MALE; NONHUMAN; PROSTATE CARCINOMA; RAT; TESTOSTERONE SYNTHESIS;

EID: 0030990505     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.11.803     Document Type: Article

References (38)

1. Dijkman GA, Debruyne FM. Epidemiology of prostate cancer. Eur Urol 1996;30:281-95.
2. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen as a screening test for prostate cancer [published erratum appears in N Engl J Med 1991;325:1324]. N Engl J Med 1991;324:1156-61.
3. Boccon-Gibod L. The management of localised cancer of the prostate. Eur Urol 1996;29 (Suppl 2):62-8.
4. Pavone-Macaluso M. Epidemiology, prevention and screening for prostate cancer. Eur Urol 1996;29(Suppl 2):49-53.
5. Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968;40:43-68.
6. Stellman SD, Wang QS. Cancer mortality in Chinese immigrants to New York City. Comparison with Chinese in Tianjin and with United States-born whites. Cancer 1994;73: 1270-5.
7. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, et al. Latent carcinoma of prostate at autopsy in seven areas. Int J Cancer 1977;20:680-8.
8. Morton MS, Griffiths K, Blacklock N. The preventive role of diet in prostatic disease. Br J Urol 1996;77:481-93.
9. Cheng E, Lee C, Grayhack J. Endocrinology of the prostate. In: Lepor H, Lawson RK, editors. Prostate diseases. Philadelphia: Saunders, 1993:57-71.
10. Pollard M, Luckert PH, Snyder DL. The promotional effect of testosterone on induction of prostate-cancer in MNU-sensitized L-W rats. Cancer Lett 1989;45:209-12.
11. Shirai T, Tamano S, Sano M, Imaida K, Hagiwara A, Futakuchi M, et al. Site-specific effects of testosterone propionate on the prostate of rat pretreated with 3,2′-dimethyl-4-aminobiphenyl:dose-dependent induction of invasive carcinomas. Jpn J Cancer Res 1995; 86:645-8.
12. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson BE. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986;76:45-8.
13. Ellis L, Nyborg H. Racial/ethnic variations in male testosterone levels: a probable contributor to group differences in health. Steroids 1992; 57:72-5.
14. Bruchovsky N, Wilson JD. The conversion of testosterone to 5-α-androstan-17β-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 1968;243:2012-21.
15. Anderson KM, Liao S. Selective retention of dihydrotestosterone by prostatic nuclei. Nature 1968;219:277-9.
16. Wilson JD. Role of dihydrotestosterone in androgen action. Prostate Suppl 1996;6:88-92.
17. Peterson RE, Imperato-McGinley J, Gautier T, Sturla E. Male pseudohermaphroditism due to steroid 5-alpha-reductase deficiency. Am J Med 1977;62:170-91.
18. Kadohama N, Karr JP, Murphy GP, Sandberg AA. Selective inhibition of prostatic tumor 5α-reductase by a 4-methyl-4-azasteroid. Cancer Res 1984;44:4947-54.
19. Lamb JC, Levy MA, Johnson RK, Isaacs JT. Response of rat and human prostatic cancers to the novel 5α-reductase inhibitor, SK&F 105657. Prostate 1992;21:15-34.
20. Lamb JC, English H, Levandoski PL, Rhodes GR, Johnson RK, Isaacs JT. Prostatic involution in rats induced by a novel 5 alpha-reductase inhibitor, SK&F 105657: role for testosterone in the androgenic response. Endocrinology 1992;130:685-94.
21. Wu AH, Whittemore AS, Kolonel LN, John EM, Gallagher RP, West DW, et al. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev 1995;4:735-41.
22. Lookingbill DP, Demers LM, Wang C, Leung A, Rittmaster RS, Santen RJ. Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J Clin Endocrinol Metab 1991;72:1242-8.
23. Meikle AW, Smith JA, Stringham JD. Production, clearance, and metabolism of testosterone in men with prostatic cancer. Prostate 1987;10: 25-31.
24. Brooks JR, Baptista EM, Berman C, Ham EA, Hichens M, Johnston DBR, et al. Response of rat ventral prostate to a new and novel 5α-reductase inhibitor. Endocrinology 1981;109: 830-6.
25. Liang T, Heiss CE, Cheung AH, Reynolds GF, Rasmusson GH. 4-Azasteroidal 5 alpha-reductase inhibitors without affinity for the androgen receptor. J Biol Chem 1984;259:734-9.
26. Hirosumi J, Nakayama O, Fagan T, Sawada K, Chida N, Inami M, et al. FK143, a novel nonsteroidal inhibitor of steroid 5α-reductase: (1) In vitro effects on human and animal prostatic enzymes. J Steroid Biochem Mol Biol 1995; 52:357-63.
27. Hirosumi J, Nakayama O, Chida N, Inami M, Fagan T, Sawada K, et al. FK143, a novel nonsteroidal inhibitor of steroid 5α-reductase: (2) In vivo effects on rat and dog prostates. J Steroid Biochem Mol Biol 1995;52:365-73.
28. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327:1185-91.
29. Brawer MK, Ellis WJ. Chemoprevention for prostate cancer. Cancer 1995;75(7 Suppl): 1783S-9S.
30. Gormley GJ. Chemoprevention strategies for prostate cancer: the role of 5 alpha-reductase inhibitors. J Cell Biochem Suppl 1992;16H: 113-7.
31. Bosland MC. Possible enhancement of prostate carcinogenesis by some chemopreventive agents. J Cell Biochem Suppl 1992;16H:135-137.
32. Albert J, Geller J, Stoeltzeng W, Loza D. An improved method for extraction and determination of prostate concentrations of endogenous androgens. J Steroid Biochem 1978;9: 717-20.
33. Kondo Y, Homma Y, Aso Y, Kakizoe T. Promotional effect of two-generation exposure to a high-fat diet on prostate carcinogenesis in ACI/Seg rats. Cancer Res 1994;54:6129-32.
34. Bosland MC. Adenocarcinoma, prostate, rat. In: Jones TC, Mohr RD, Hunt RD, editors, Monographs on the pathology of laboratory animals. Vol 5. Berlin: Springer-Verlag, 1987: 252-72.
35. Isaacs JT. The aging ACI/Seg versus Copenhagen male rat as a model system for the study of prostatic carcinogenesis. Cancer Res 1984; 44:5785-96.
36. Rittmaster RS, Manning AP, Wright AS, Thomas LN, Whitefield S, Norman RW, et al. Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5α-reductase inhibitor finasteride. Endocrinology 1995;136: 741-8.
37. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992;74: 505-8.
38. Grino PB, Griffin JE, Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 1990;126:1165-72.